Ignite Creation Date:
2025-12-24 @ 3:53 PM
Ignite Modification Date:
2026-01-31 @ 4:49 AM
Study NCT ID:
NCT02589392
Status:
COMPLETED
Last Update Posted:
2024-02-26
First Post:
2015-10-23
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Cetaphil Restoraderm Effect on Young Children With Atopic Dermatitis
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003876', 'term': 'Dermatitis, Atopic'}], 'ancestors': [{'id': 'D012873', 'term': 'Skin Diseases, Genetic'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D003872', 'term': 'Dermatitis'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D017443', 'term': 'Skin Diseases, Eczematous'}, {'id': 'D006969', 'term': 'Hypersensitivity, Immediate'}, {'id': 'D006967', 'term': 'Hypersensitivity'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'stephanie.leclerc@galderma.com', 'phone': '+33492386706', 'title': 'Stéphanie Leclerc', 'organization': 'Galderma'}, 'certainAgreement': {'otherDetails': "There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. Disclosure agreement covered by contract.", 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': '8 months', 'description': 'Analysis was based on safety population that included all treated population.', 'eventGroups': [{'id': 'EG000', 'title': 'Moisturizer + Body Wash', 'description': 'Cetaphil® Restoraderm® moisturizer (2/day) + Cetaphil® Restoraderm® Skin body wash (1/day)\n\nCetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash', 'otherNumAtRisk': 60, 'deathsNumAtRisk': 60, 'otherNumAffected': 14, 'seriousNumAtRisk': 60, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Body Wash', 'description': 'Cetaphil® Restoraderm® body wash (1/day)\n\nCetaphil® Restoraderm® body wash', 'otherNumAtRisk': 60, 'deathsNumAtRisk': 60, 'otherNumAffected': 17, 'seriousNumAtRisk': 60, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'PYREXIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 60, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 60, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 16.0'}, {'term': 'NASOPHARYNGITIS', 'stats': [{'groupId': 'EG000', 'numAtRisk': 60, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 60, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 16.0'}, {'term': 'UPPER RESPIRATORY TRACT INFECTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 60, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 60, 'numEvents': 8, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 16.0'}, {'term': 'COUGH', 'stats': [{'groupId': 'EG000', 'numAtRisk': 60, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 60, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 16.0'}, {'term': 'URTICARIA', 'stats': [{'groupId': 'EG000', 'numAtRisk': 60, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 60, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 16.0'}, {'term': 'VIRAL INFECTION', 'stats': [{'groupId': 'EG000', 'numAtRisk': 60, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 60, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 16.0'}], 'frequencyThreshold': '2'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Time to Relapse (Quantile 25%)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '60', 'groupId': 'OG000'}, {'value': '60', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Moisturizer + Body Wash', 'description': 'Cetaphil® Restoraderm® moisturizer (2/day) + Cetaphil® Restoraderm® Skin body wash (1/day)\n\nCetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash'}, {'id': 'OG001', 'title': 'Body Wash', 'description': 'Cetaphil® Restoraderm® body wash (1/day)\n\nCetaphil® Restoraderm® body wash'}], 'classes': [{'categories': [{'measurements': [{'value': '48', 'groupId': 'OG000', 'lowerLimit': '11', 'upperLimit': '86'}, {'value': '15', 'groupId': 'OG001', 'lowerLimit': '8', 'upperLimit': '27'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'The duration between Baseline and the first AD relapse occurred (up to 89 days)', 'description': 'Time to relapse corresponds to date of relapse - date of baseline. Quantile 25% replaced the median time to relapse that was not reached.', 'unitOfMeasure': 'Days', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on intent-to-treat efficacy (ITT) population that included all participants who were enrolled and randomized.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Moisturizer + Body Wash', 'description': 'Cetaphil® Restoraderm® moisturizer (2/day) + Cetaphil® Restoraderm® Skin body wash (1/day)\n\nCetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash'}, {'id': 'FG001', 'title': 'Body Wash', 'description': 'Cetaphil® Restoraderm® body wash (1/day)\n\nCetaphil® Restoraderm® body wash'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '60'}, {'groupId': 'FG001', 'numSubjects': '60'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '54'}, {'groupId': 'FG001', 'numSubjects': '54'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '6'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'Sponsor decision to withdraw subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '60', 'groupId': 'BG000'}, {'value': '60', 'groupId': 'BG001'}, {'value': '120', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Moisturizer + Body Wash', 'description': 'Cetaphil® Restoraderm® moisturizer (2/day) + Cetaphil® Restoraderm® Skin body wash (1/day)\n\nCetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash'}, {'id': 'BG001', 'title': 'Body Wash', 'description': 'Cetaphil® Restoraderm® body wash (1/day)\n\nCetaphil® Restoraderm® body wash'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '5.9', 'spread': '2.9', 'groupId': 'BG000'}, {'value': '5.9', 'spread': '2.9', 'groupId': 'BG001'}, {'value': '5.9', 'spread': '2.9', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '37', 'groupId': 'BG000'}, {'value': '33', 'groupId': 'BG001'}, {'value': '70', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '23', 'groupId': 'BG000'}, {'value': '27', 'groupId': 'BG001'}, {'value': '50', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '60', 'groupId': 'BG000'}, {'value': '58', 'groupId': 'BG001'}, {'value': '118', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Skin phototype', 'classes': [{'title': 'II', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}]}, {'title': 'III', 'categories': [{'measurements': [{'value': '17', 'groupId': 'BG000'}, {'value': '20', 'groupId': 'BG001'}, {'value': '37', 'groupId': 'BG002'}]}]}, {'title': 'IV', 'categories': [{'measurements': [{'value': '43', 'groupId': 'BG000'}, {'value': '39', 'groupId': 'BG001'}, {'value': '82', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'description': 'Skin phototype definitions according to T.B. Fitzpatrick. This was assessed by the investigator at baseline as:\n\nII: Always burns easily; tans minimally and with difficulty III:Burns minimally; tans gradually and uniformly (light brown) IV: Burns minimally; always tans well (moderate brown)', 'unitOfMeasure': 'participants'}, {'title': 'Atopic Dermatitis (AD) duration', 'classes': [{'categories': [{'measurements': [{'value': '2.9', 'spread': '3.4', 'groupId': 'BG000'}, {'value': '2.7', 'spread': '2.9', 'groupId': 'BG001'}, {'value': '2.8', 'spread': '3.1', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Number of AD acute phase in the last 12 months', 'classes': [{'categories': [{'measurements': [{'value': '4.1', 'spread': '3.7', 'groupId': 'BG000'}, {'value': '3.7', 'spread': '3.3', 'groupId': 'BG001'}, {'value': '3.9', 'spread': '3.5', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'episodes', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Duration of the last acute phase', 'classes': [{'categories': [{'measurements': [{'value': '27.9', 'spread': '40.8', 'groupId': 'BG000'}, {'value': '27.0', 'spread': '53.5', 'groupId': 'BG001'}, {'value': '27.4', 'spread': '47.3', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'days', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Severity of the last AD acute phase', 'classes': [{'categories': [{'title': 'Mild', 'measurements': [{'value': '44', 'groupId': 'BG000'}, {'value': '41', 'groupId': 'BG001'}, {'value': '85', 'groupId': 'BG002'}]}, {'title': 'Moderate', 'measurements': [{'value': '16', 'groupId': 'BG000'}, {'value': '19', 'groupId': 'BG001'}, {'value': '35', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': "Investigator's Global Assessment (IGA)", 'classes': [{'categories': [{'title': '0-Clear', 'measurements': [{'value': '20', 'groupId': 'BG000'}, {'value': '22', 'groupId': 'BG001'}, {'value': '42', 'groupId': 'BG002'}]}, {'title': '1-Almost clear', 'measurements': [{'value': '40', 'groupId': 'BG000'}, {'value': '38', 'groupId': 'BG001'}, {'value': '78', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'The investigator assessed the global AD severity measurement of erythema and infiltration/papules using IGA on a 6-point scale ranging from 0 = clear (no inflammatory signs of AD) ; 1 = almost clear; 2 = mild disease; 3 = moderate disease, 4 = severe disease; and 5 = very severe disease (severe erythema and severe papulation/infiltration with oozing/crusting), where higher score indicated worst symptoms and decrease in score relates to an improvement in signs and symptoms.', 'unitOfMeasure': 'Participants'}, {'title': 'Eczema Area and Severity Index (EASI)', 'classes': [{'title': 'Erythema', 'categories': [{'measurements': [{'value': '0.13', 'spread': '0.21', 'groupId': 'BG000'}, {'value': '0.10', 'spread': '0.17', 'groupId': 'BG001'}, {'value': '0.12', 'spread': '0.19', 'groupId': 'BG002'}]}]}, {'title': 'infiltration / Papulation', 'categories': [{'measurements': [{'value': '0.09', 'spread': '0.19', 'groupId': 'BG000'}, {'value': '0.08', 'spread': '0.17', 'groupId': 'BG001'}, {'value': '0.09', 'spread': '0.18', 'groupId': 'BG002'}]}]}, {'title': 'Excoriation', 'categories': [{'measurements': [{'value': '0.07', 'spread': '0.15', 'groupId': 'BG000'}, {'value': '0.10', 'spread': '0.21', 'groupId': 'BG001'}, {'value': '0.08', 'spread': '0.18', 'groupId': 'BG002'}]}]}, {'title': 'Lichenification', 'categories': [{'measurements': [{'value': '0.04', 'spread': '0.10', 'groupId': 'BG000'}, {'value': '0.02', 'spread': '0.07', 'groupId': 'BG001'}, {'value': '0.03', 'spread': '0.09', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'description': 'The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicated the worse severity of AD.', 'unitOfMeasure': 'scores on a scale', 'dispersionType': 'STANDARD_DEVIATION'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['INVESTIGATOR']}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 120}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-05-29', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-02', 'completionDateStruct': {'date': '2016-02-03', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-12', 'studyFirstSubmitDate': '2015-10-23', 'resultsFirstSubmitDate': '2018-02-15', 'studyFirstSubmitQcDate': '2015-10-27', 'lastUpdatePostDateStruct': {'date': '2024-02-26', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2024-02-12', 'studyFirstPostDateStruct': {'date': '2015-10-28', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2024-02-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2016-02-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Time to Relapse (Quantile 25%)', 'timeFrame': 'The duration between Baseline and the first AD relapse occurred (up to 89 days)', 'description': 'Time to relapse corresponds to date of relapse - date of baseline. Quantile 25% replaced the median time to relapse that was not reached.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Atopic Dermatitis']}, 'referencesModule': {'references': [{'pmid': '29143926', 'type': 'DERIVED', 'citation': 'Ma L, Li P, Tang J, Guo Y, Shen C, Chang J, Kerrouche N. Prolonging Time to Flare in Pediatric Atopic Dermatitis: A Randomized, Investigator-Blinded, Controlled, Multicenter Clinical Study of a Ceramide-Containing Moisturizer. Adv Ther. 2017 Dec;34(12):2601-2611. doi: 10.1007/s12325-017-0640-6. Epub 2017 Nov 16.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the effect of Cetaphil® Restoraderm® skin restoring moisturizer in reducing the signs and symptoms of very dry atopic skin in young children. Subjects with atopic dermatitis (AD) in remission phase will be randomized to receive either Cetaphil® Restoraderm® skin restoring body wash only, or the same body wash in association with Cetaphil® Restoraderm® skin restoring moisturizer.', 'detailedDescription': 'Two groups randomized in a ratio of \\[1:1\\] for a 12-week period Five study evaluation were planned: at Baseline, week 2, Week 4, Week8 and Week12'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD'], 'maximumAge': '12 Years', 'minimumAge': '2 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Male or female subject, aged 2 to 12 years inclusive\n* Controlled mild to moderate atopic dermatitis with a Investigator Global Assessment score at 0 or 1, within one week after successful treatment with topical corticosteroid.\n\nExclusion Criteria:\n\n* Subject presenting bacterial, viral, fungal or parasite skin infection\n* Subject with ulcerated lesions, acne or rosacea\n* Immunosuppression\n* Subject with a wash-out period from baseline for topical treatment less than 8 days for Calcineurin inhibitor\n* Subject with a wash-out period from baseline for topical treatment more than 8 days for corticosteroid\n* Subject with a wash-out period from baseline for systemic treatment less than 8 days for anti-histamines, less than 4 weeks for immunomodulators'}, 'identificationModule': {'nctId': 'NCT02589392', 'briefTitle': 'Cetaphil Restoraderm Effect on Young Children With Atopic Dermatitis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Galderma R&D'}, 'officialTitle': 'Effect of Cetaphil® Restoraderm® Moisturizer on Very Dry Skin in Children With a Controlled Atopic Dermatitis:a Randomised, Parallel Group Study', 'orgStudyIdInfo': {'id': 'RD.03.SPR.29110'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Moisturizer + Body wash', 'description': 'Cetaphil® Restoraderm® moisturizer (2/day) + Cetaphil® Restoraderm® Skin body wash (1/day)', 'interventionNames': ['Other: Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Body wash', 'description': 'Cetaphil® Restoraderm® body wash (1/day)', 'interventionNames': ['Other: Cetaphil® Restoraderm® body wash']}], 'interventions': [{'name': 'Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash', 'type': 'OTHER', 'armGroupLabels': ['Moisturizer + Body wash']}, {'name': 'Cetaphil® Restoraderm® body wash', 'type': 'OTHER', 'armGroupLabels': ['Body wash']}]}, 'contactsLocationsModule': {'locations': [{'zip': '518026', 'city': 'Shenzhen', 'state': 'Guangdong', 'country': 'China', 'facility': "Department of Dermatology /Shenzhen Children's hospital", 'geoPoint': {'lat': 22.54554, 'lon': 114.0683}}, {'zip': '410007', 'city': 'Hunan', 'state': 'Hunan', 'country': 'China', 'facility': "Hunan Children's Hospital"}, {'zip': '200092', 'city': 'Yangpu', 'state': 'Shanghai Municipality', 'country': 'China', 'facility': 'XinHua Hospital', 'geoPoint': {'lat': 31.26193, 'lon': 121.51904}}, {'zip': '100045', 'city': 'Beijing', 'state': 'XI Cheng', 'country': 'China', 'facility': "Department of Dermatology /Beijing Children's Hospital", 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '1000', 'city': 'Manila', 'state': 'Ermita', 'country': 'Philippines', 'facility': 'Philippine General Hospital', 'geoPoint': {'lat': 14.6042, 'lon': 120.9822}}, {'zip': '1780', 'city': 'Manila', 'state': 'Muntinlupa City', 'country': 'Philippines', 'facility': 'Asian Hospital and Medical Center', 'geoPoint': {'lat': 14.6042, 'lon': 120.9822}}, {'zip': '1634', 'city': 'City of Taguig', 'state': 'Taguig City', 'country': 'Philippines', 'facility': "St. Luke's Medical Center", 'geoPoint': {'lat': 14.5243, 'lon': 121.0792}}, {'zip': '1003', 'city': 'Manila', 'country': 'Philippines', 'facility': 'Jose R. Reyes Memorial Medical Center', 'geoPoint': {'lat': 14.6042, 'lon': 120.9822}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Galderma R&D', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}